Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last?

Company Overview - Hims & Hers Health, Inc. (HIMS) shares increased by 5.7% to close at $34.75, following a notable trading volume, despite a 50.5% loss over the past four weeks [1] - The company reported a 95% year-over-year increase in quarterly revenue to$ 246.6 million and a 65% full-year revenue growth to $872 million, alongside positive adjusted EBITDA margins [2] - Hims & Hers projects revenue between$ 1.17 billion and $1.20 billion for 2025, indicating continued profitability and growth potential [2] Earnings Expectations - The upcoming quarterly earnings are expected to be$ 0.11 per share, reflecting a year-over-year change of +120%, with revenues anticipated at $535.94 million, up 92.7% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 18% lower over the last 30 days, which may impact future price appreciation [4] Industry Context - Hims & Hers Health operates within the Zacks Medical Info Systems industry, where another company, Fulgent Genetics, Inc. (FLGT), has seen a 1.2% increase in its stock price [4] - Fulgent Genetics has experienced a significant downward revision of its EPS estimate by 26.9% over the past month, indicating a challenging outlook compared to the previous year [5]